Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial

Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in patients with non-diabetic C...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Wei, Yang, Nizhi, Zhang, Lei, Li, Chuang, Wu, Yifan, Ouyang, Wenwei, Xu, Peng, Zou, Chuan, Pei, Chunpeng, Shi, Wei, Zhan, Jihong, Yang, Hongtao, Chen, Hongyu, Wang, Xiaoqin, Tian, Yun, Yuan, Fang, Sun, Wei, Xiong, Guoliang, Chen, Ming, Guan, Jianguo, Tang, Shuifu, Zhang, Chunyan, Liu, Yuning, Deng, Yueyi, Lin, Qizhan, Lu, Fuhua, Hong, Weihong, Yang, Aicheng, Fang, Jingai, Rao, Jiazhen, Wang, Lixin, Bao, Kun, Lin, Feng, Xu, Yuan, Lu, Zhaoyu, Su, Guobin, Zhang, La, Johnson, David W, Zhao, Daixin, Hou, Haijing, Fu, Lizhe, Guo, Xinfeng, Yang, Lihong, Qin, Xindong, Wen, Zehuai, Liu, Xusheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941267/
https://www.ncbi.nlm.nih.gov/pubmed/33708125
http://dx.doi.org/10.3389/fphar.2020.627185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941267/
https://www.ncbi.nlm.nih.gov/pubmed/33708125
http://dx.doi.org/10.3389/fphar.2020.627185

Ejemplares similares